• Antigen-centric tumor immunity became a central research theme, correlating cellular and humoral responses with tumor-associated antigens identified in melanomas and other neoplasms; serology and cell-based assays mapped antigenic systems and cross-type targets [19], [5], [20], [11], [6].

• Blocking and blocking-factor phenomena revealed that sera from tumor-bearing hosts can hinder cytotoxic lymphocytes, with blocking factors eluted from tumors and restored after low-pH treatment; this shaped views on immune regulation in cancer [4], [9], [16], [17], [3].

• Colony inhibition assays emerged as a unifying in vitro paradigm to quantify lymphoid destruction of tumor cells and to study serum effects, cross-species, involving mouse, rabbit, and human systems; foundational CI work spanned 1967-1970s [7], [18], [17], [8].

• Cytokine-driven modulation and regulatory mechanisms shaped immunotherapy concepts, with IL-2–mediated activation (Lymphokine-activated killer cells), IL-2 gene transfer to tumor cells, and T-cell–mediated suppression illustrating the dynamic balance of anti-tumor immunity [13], [15], [10].